Domů › Akutní myeloidní leukemie › Kalifornie › Los Angeles
Klinické studie Akutní myeloidní leukemie v Los Angeles, CA
24 studií pro Akutní myeloidní leukemie hledá účastníky v lokalitách v Los Angeles a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Probíhá náborFáze 2
- Cedars-Sinai Medical Center, Los Angeles
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Cedars-Sinai Medical Center, Los Angeles
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Cedars-Sinai Medical Center, Los Angeles
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Cedars-Sinai Medical Center, Los Angeles
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Probíhá náborFáze 3
- Children's Hospital Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Mattel Children's Hospital UCLA, Los Angeles
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Probíhá náborFáze 2
- USC Norris Comprehensive Cancer Center, Los Angeles
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Probíhá náborFáze 2
- UCLA Medical Center, Los Angeles
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Probíhá náborFáze 3
- US-Los Angeles CA-UCLA, Los Angeles
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Probíhá náborFáze 3
- US-Los Angeles CA-UCLA, Los Angeles
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Probíhá náborFáze 1/2
- Children's Hospital Los Angeles, Los Angeles
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Probíhá náborFáze 3
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles, Los Angeles
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Health - Bowyer Oncology Center, Los Angeles
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Probíhá náborFáze 3
- University of California Los Angeles (UCLA) - David Geffen School of Medicine, Los Angeles
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Probíhá náborFáze 2
- UCLA Department of Medicine, Los Angeles
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Probíhá náborObservační studie
- UCLA, Los Angeles
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Probíhá náborObservační studie
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Probíhá náborFáze 2/3
- Keck School of Medicine of USC, Los Angeles
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Probíhá náborFáze 1
- USC / Norris Comprehensive Cancer Center, Los Angeles
- UCLA - Bowyer Oncology Center, Los Angeles
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Probíhá náborFáze 1
- UCLA, Los Angeles
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Probíhá náborFáze 1
- University of California Los Angeles, Los Angeles
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Probíhá náborFáze 1
- UCLA Medical Center, Los Angeles
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Probíhá náborFáze 2
- UCLA Medical Center, Los Angeles
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Probíhá náborFáze 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Studie Akutní myeloidní leukemie v jiných městech
- Houston, TX85 studií
- New York City, NY51 studií
- Boston, MA44 studií
- Seattle, WA41 studií
- Baldwin Park, CA40 studií
- Columbus, OH35 studií
- Philadelphia, PA34 studií
- Durham, NC33 studií
- Atlanta, GA31 studií
- Tampa, FL29 studií
- Chicago, IL26 studií
- Portland, OR25 studií
Další studie v Los Angeles
- Nemalobuněčný plicní karcinom87 studií
- Rakovina (všechny typy)74 studií
- Rakovina prsu73 studií
- Rakovina prostaty61 studií
- Kolorektální karcinom59 studií
- Metastatický karcinom57 studií
- Rakovina vaječníků50 studií
- Rakovina plic45 studií
- Squamózní buněčný karcinom hlavy a krku42 studií
- Rakovina slinivky břišní35 studií
- Rakovina endometria34 studií
- Melanom34 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.